NEW YORK, May 1 – Protein structure determination company Signature BioScience said Tuesday it had appointed David Spellmeyer chief scientific officer and vice president of drug discovery.
Spellmeyer will be in charge of developing Signature BioScience’s new drug discovery efforts and validating the company’s technology.
Previously Spellmeyer was executive director at DuPont Pharmaceuticals Research Laboratories, where he oversaw the computational chemistry aspects of drug discovery and information technologies.
The San Francisco-based company also named Nancy Pecota senior director of finance and administration. Pecota was recently director of finance and accounting at Aclara BioSciences, where she was part of the management team that successfully took the company public.
Signature BioScience, an early stage proteomics company, has adapted telecommunications and computer chip technology to determine the structure and homology of classes of proteins.